Investegate |Centessa Pharmaceuticals plc Announcements | Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors

Investegate announcements from Centessa Pharmaceuticals plc, Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors

Related Keywords

Boston ,Massachusetts ,United States ,Russia ,London ,City Of ,United Kingdom ,Ukraine ,Kristenk Sheppard , ,Exchange Commission ,Centessa Pharmaceuticals Announces ,Drug Administration ,Centessa Pharmaceuticals ,Nasdaq ,Clinical Trial ,First Lockbody ,Investigational New Drug ,Saurabh Saha ,Chief Executive Officer ,Annual Report ,Quarterly Reports ,Investegate Announcements ,Investegate Company Announcements ,Centessa Pharmaceuticals Plc ,Lobenewswire ,Lobenewswire And Globenewswire ,Nw ,